Piazza Maria Francesca, Amicizia Daniela, Marchini Francesca, Astengo Matteo, Grammatico Federico, Battaglini Alberto, Sticchi Camilla, Paganino Chiara, Lavieri Rosa, Andreoli Giovanni Battista, Orsi Andrea, Icardi Giancarlo, Ansaldi Filippo
Regional Health Agency of Liguria (ALiSa), 16121 Genoa, Italy.
Department of Health Sciences (DiSSal), University of Genoa, 16132 Genoa, Italy.
Vaccines (Basel). 2022 Nov 8;10(11):1885. doi: 10.3390/vaccines10111885.
The SARS-CoV-2 pandemic continues to spread worldwide, generating a high impact on healthcare systems. The aim of the study was to examine the epidemiological burden of SARS-CoV-2 reinfections and to identify potential related risk factors. A retrospective observational study was conducted in Liguria Region, combining data from National Vaccines Registry and Regional Chronic Condition Data Warehouse. In the study period (September 2021 to May 2022), 335,117 cases of SARS-CoV-2 infection were recorded in Liguria, of which 15,715 were reinfected once. During the Omicron phase (which predominated from 3 January 2022), the risk of reinfection was 4.89 times higher (p < 0.001) than during the Delta phase. Unvaccinated and vaccinated individuals with at least one dose for more than 120 days were at increased risk of reinfection compared with vaccinated individuals with at least one dose for ≤120 days, respectively (odds ratio (OR) of 1.26, p < 0.001; OR of 1.18, p < 0.001). Healthcare workers were more than twice as likely to be reinfected than non-healthcare workers (OR of 2.38, p < 0.001). Lower ORs were seen among people aged 60 to 79 years. Two doses or more of vaccination were found to be protective against the risk of reinfection rather than a single dose (mRNA vaccines: OR of 0.06, p < 0.0001, and OR of 0.1, p < 0.0001; vector vaccines: OR of 0.05, p < 0.0001). Patients with chronic renal failure, cardiovascular disease, bronchopneumopathy, neuropathy and autoimmune diseases were at increased risk of reinfection (OR of 1.38, p = 0.0003; OR of 1.09, p < 0.0296; OR of 1.14, p = 0.0056; OR of 1.78, p < 0.0001; OR of 1.18, p = 0.0205). Estimating the epidemiological burden of SARS-CoV-2 reinfections and the role played by risk factors in reinfections is relevant for identifying risk-based preventive strategies in a pandemic context characterized by a high circulation of the virus and a high rate of pathogen mutations.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)大流行仍在全球范围内蔓延,对医疗系统产生了重大影响。本研究的目的是调查SARS-CoV-2再次感染的流行病学负担,并确定潜在的相关风险因素。在利古里亚地区进行了一项回顾性观察研究,整合了国家疫苗登记处和地区慢性病数据仓库的数据。在研究期间(2021年9月至2022年5月),利古里亚记录了335117例SARS-CoV-2感染病例,其中15715例曾再次感染。在奥密克戎阶段(2022年1月3日起占主导),再次感染的风险比德尔塔阶段高4.89倍(p<0.001)。与接种至少一剂疫苗且时间≤120天的个体相比,未接种疫苗以及接种至少一剂疫苗超过120天的个体再次感染的风险增加(优势比(OR)分别为1.26,p<0.001;OR为1.18,p<0.001)。医护人员再次感染的可能性是非医护人员的两倍多(OR为2.38,p<0.001)。60至79岁人群的OR值较低。发现接种两剂或更多剂疫苗对再次感染风险具有保护作用,而单剂接种则不然(信使核糖核酸(mRNA)疫苗:OR为0.06,p<0.0001,OR为0.1,p<0.0001;载体疫苗:OR为0.05,p<0.0001)。慢性肾衰竭、心血管疾病、支气管肺炎、神经病变和自身免疫性疾病患者再次感染的风险增加(OR分别为1.38,p=0.0003;OR为1.09,p<0.0296;OR为1.14,p=0.0056;OR为1.78,p<0.0001;OR为1.18,p=0.0205)。评估SARS-CoV-2再次感染的流行病学负担以及风险因素在再次感染中所起的作用,对于在病毒高传播和病原体高突变率的大流行背景下确定基于风险的预防策略具有重要意义。